Caliway Biopharmaceuticals C, TW0006919004

Caliway Biopharmaceuticals stock: China trial cleared

Published on 11/11/2026 at 10:45 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Caliway Biopharmaceuticals stock has a new China development milestone after CBL-0102 received authorization to proceed. Enrollment is expected in December 2026.

China trial moves toward enrollment

Caliway said China authorized its CBL-0102 clinical study for CBL-514 to proceed.
Enrollment is expected to start in December 2026, with clinical data anticipated in the second quarter of 2027.
The study will assess pharmacokinetics, safety and tolerability in about 30 healthy subjects.

Caliway Biopharmaceuticals C, TW0006919004, Illustration mit AI erstellt.

Caliway Biopharmaceuticals announced on November 6 that China authorized its CBL-0102 clinical study for CBL-514 to proceed. The company described the clearance as ahead of schedule in its official announcement.

China study sets next milestone

The trial is expected to begin enrolling participants in December 2026. Caliway expects the study to be completed in the second quarter of 2027, with clinical data anticipated shortly afterward.

CBL-0102 is designed as a randomized, open-label, single-dose, parallel-design study involving approximately 30 healthy subjects at two sites in China. It will assess ethnicity sensitivity, pharmacokinetics, safety and tolerability across different dose levels.

Regulatory path remains in development

The China study is intended to support the broader development of CBL-514 in Asia. Caliway said results could provide input for future Phase 3 studies and regulatory submissions in China and other Asian markets.

CBL-514 remains an investigational injectable candidate for localized subcutaneous fat reduction. The Chinese authorization covers the clinical study and does not represent a commercial launch.